We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Snibe Co.,Ltd.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a global leader in the IVD field, with 30 years o... read more Featured Products: More products

Download Mobile App





SNIBE Brings Latest Innovations in Immunoassay, Clinical Biochemistry and Molecular Diagnostics to Medlab Middle East 2023

By LabMedica International staff writers
Posted on 09 Feb 2023

SNIBE (Shenzhen, China) is bringing its latest innovations, including new members from its product lines in immunoassay, clinical biochemistry and molecular diagnostics to Medlab Middle East 2023. More...

At Medlab Middle East 2023, SNIBE is showcasing Biolumi CX8, the new lab booster that combines one of the fastest immunoassay system MAGLUMI X8, and the biochemical system Biossays C8, with ultra-high throughput in a very small footprint. Moreover, it can also be customized according to specific needs, supporting up to four connected instruments, and covering the requirements of different laboratories. SNIBE is also showcasing the MAGLUMI X6 flexible CLIA solution that is designed for medium/high-volume laboratories. The MAGLUMI X6 offers flexible configuration modules and features new generation hydraulic TIP pipetting technology. It has a high speed of 450 tests/hour and is suitable for 155 chemiluminescence immunoreagents.

In addition, SNIBE is highlighting the Molecision S6 automated, integrated digital PCR system that provides a full-platform solution for research/in vitro diagnostics. Molecision S6 uses a cutting-edge cartridge that provides uniform droplets and prevents contamination, maximizing operation productivity and cost efficiency. Light oil is pre-filled in the cartridge so that the droplets can be sunk under the light oil to ensure a fully enclosed condition, achieving a sensitivity of 0.002%. Its highly integrated design and optimized system make it space-saving and easy to use. Alongside the Molecision S6, SNIBE is highlighting the Molecision MP-32 and MP-96 fully-auto nucleic acid purification systems that adopt a high-performance magnetic extraction method, thereby maximizing the recovery rate and consistency of results.

Related Links:
SNIBE


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Hematology Consumables
Bioblood Devices
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: The proposed workflow adds liquid biopsy to detect genetic and molecular signs of cancer in CSF samples already collected during autoimmune encephalitis evaluation. (Image Credit: Shutterstock)

CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation

Autoimmune encephalitis can cause memory and behavioral changes, seizures, and altered consciousness, but diagnosis can be challenging because cancers involving the brain and central nervous system may... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.